The Quantellect read.As of Nov 19, 2026, 5 active firms cover Corcept Therapeutics Incorporated: 4 rate it Buy or better, 0 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. The target range is very wide, $50.00 to $165.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $122.60 sits 81% above the current $67.78. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.84 next quarter toward $4.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy480%
Neutral00%
Sell120%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$122.60
+80.9% upside
Average target across 5 active firms as of Nov 19, 2026 vs $67.78 current
Highest Target$165.00
Average Target$122.60
Lowest Target$50.00
Detailed analyst forecasts for CORT
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate CORT a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CORT EPS & revenue forecast
EPS · NEXT QUARTER
$0.84
Range $0.60 – $1.09 · 2 analysts · -382% YoY
Next period, 2 analysts expect Corcept Therapeutics Incorporated to earn $0.84 a share (range $0.60 – $1.09), versus $-0.30 a year earlier. Full-year consensus is $2.30, growing to $4.98 the year after.
REVENUE · NEXT QUARTER
$374.2M
Range $345.6M – $400.0M · 2 analysts · +127% YoY
Revenue is expected to reach $374.2M (range $345.6M – $400.0M), +126.9% year-over-year. Full-year consensus is $1.2B, rising to $1.7B next year.
Top analysts covering Corcept Therapeutics Incorporated
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CORT.
#1
David Amsellem
Piper Sandler · Rank #124
Buy
$165.00+143.4% to target
Overall win rate
50%
+ Follow
#2
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$161.00+137.5% to target
Overall win rate
44%
+ Follow
#3
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$165.00+143.4% to target
Overall win rate
38%
+ Follow
#4
KP
Kalpit Patel
Wolfe Research
Sell
$50.00-26.2% to target
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Buy
$72.00+6.2% to target
Coverage
—
+ Follow
CORT stock forecast FAQ
What is CORT's average 12-month price target?+
The 5 active firms with a live target average $122.60 for Corcept Therapeutics Incorporated over the next 12 months, ranging from a $165.00 high to a $50.00 low, as of Nov 19, 2026.
Is CORT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CORT?+
The Street-high target is $165.00 (HC Wainwright & Co.), and the Street-low is $50.00 (Wolfe Research). The average of all 5 active-firm targets is $122.60.
How many active Wall Street firms cover CORT?+
5 active firms have a recognized rating on Corcept Therapeutics Incorporated as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CORT?+
Among analysts who currently cover CORT, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #124). Their current call is Buy with a $165.00 target.
What is Corcept Therapeutics Incorporated's projected EPS for next quarter?+
The consensus estimate is $0.84 per share (range $0.60 – $1.09) across 2 analysts. Full-year EPS is projected at $2.30, rising to $4.98 the following year.
How much revenue is Corcept Therapeutics Incorporated expected to report next quarter?+
Consensus revenue is $374.2M (range $345.6M – $400.0M). Full-year revenue is projected at $1.2B, growing to $1.7B next year.
Have analysts been upgrading or downgrading CORT lately?+
As of Nov 19, 2026, 4 of 5 active firms rate CORT a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CORT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.